Tests AHB-137 injection in adults with chronic hepatitis B and low HBsAg
Tests AHB-137 injection in adults with chronic hepatitis B and low HBsAg.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)
Key facts
- Where
- Beijing, Changzhou, Chengdu, Chongqing, Guangzhou, Hangzhou, Jilin City, Nanning, Shenzhen, Xiamen, and Zhengzhou, ChinaSee the 11 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07137910, who can take part
Where in China
- BeijingBeijing, ChinaTaking people
- ChangzhouChangzhou, ChinaNot yet recruiting
- ChengduChengdu, ChinaNot yet recruiting
- ChongqingChongqing, ChinaNot yet recruiting
- GuangzhouGuangzhou, ChinaNot yet recruiting
- HangzhouHangzhou, ChinaNot yet recruiting
- Jilin CityJilin City, ChinaTaking people
- NanningNanning, ChinaTaking people
- ShenzhenShenzhen, ChinaNot yet recruiting
- XiamenXiamen, ChinaTaking people
- ZhengzhouZhengzhou, ChinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ausper Biopharma Co., Ltd.
- Trial code
- NCT07137910
- Record updated
- 5 August 2026
- Original description
This is an open-label, multicenter, Phase 2 study designed to evaluate the efficacy and safety of AHB-137 injection in participants with chronic hepatitis B (CHB) with low hepatitis B surface antigen (HBsAg) levels.Read full original descriptionShow less
An Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Low-HBsAg Chronic Hepatitis B
This is an open-label, multicenter, Phase 2 study designed to evaluate the efficacy and safety of AHB-137 injection in participants with chronic hepatitis B (CHB) with low hepatitis B surface antigen (HBsAg) levels.
Inclusion: Voluntarily participate in the study and sign the informed consent form; 18-65 years of age (including boundary values) ; Body mass index met the requirements; Participants with CHB who are HBsAg or HBV DNA positive for at least 6 months; Meet the relevant requirements for prior medications; HBsAg and HBV DNA and liver function indicators meet the requirements; Effective contraception as required.
Exclusion: Participants with recent major trauma or major surgery, or planning surgery; Those who are participating in another clinical trial, or have not undergone a protocol-specified washout period prior to this study; Prior/current use of prohibited medications; Uncontrolled and stable clinically significant abnormalities other than a history of CHB infection; Associated liver disease; Any serious infection other than CHB infection requires intravenous anti-infective therapy; HCV RNA positive, HIV antibody positive, syphilis positive; Diseases associated with vascular inflammatory conditions; History of malignancy or ongoing assessment of possible malignancy; History of allergies, or allergic constitution; Abnormal laboratory results; QT interval corrected heart rate (Fridericia method) abnormal; Inappropriate for participation in this trial as judged by the investigator.